Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
-
Scotland's Laidlaw extends tenure as Hurricanes coach
-
Messi scores 900th career goal but Miami crash out
-
Japan coach says Australia 'massive favourites' in Asian Cup final
-
Iran targets Gulf energy sites after gas field strike
-
Director plans to put Val Kilmer back on screen thanks to AI
-
Social media addiction trial jury deliberations continue
-
Messi scores 900th career goal in Inter Miami cup clash
-
Barcelona, Liverpool, Bayern and Atletico reach Champions League quarter-finals
-
Tudor impressed by 'improved' Spurs despite Champions League exit
-
PSG will not relish Liverpool reunion, says Slot
-
Kane says Bayern 'don't fear anyone' ahead of Real clash
-
Venezuelan leader sacks defense minister, a Maduro stalwart
-
Kane and Bayern swat aside Atalanta to set up Real clash
-
Thailand's new parliament set to elect Anutin as PM
-
Atletico survive Spurs scare to reach Champions League quarters
-
Liverpool thrash Galatasaray to reach Champions League quarters
-
Costa Rica cuts ties with Cuba, closes embassy in Havana
-
Music popstar will.i.am meshes AI and 'micromobility'
-
US Fed Chair says 'no intention' of leaving board while probe ongoing
-
Iran targets Gulf energy sites after intel chief killed
-
Colombia detains alleged mastermind of Ecuadoran candidate assassination
-
Costa Rica closes Havana embassy, tells Cuba to withdraw diplomats
-
NY's New Museum returns contemporary to heart of Manhattan
-
Cesar Chavez, icon of US labor movement, accused of serial sex abuse: report
-
Barcelona demolish Newcastle 7-2 to reach Champions League quarters
-
Trump nominee for Homeland Security chief grilled at fiery Senate hearing
-
First international aid convoy arrives in crisis-hit Cuba
-
Eight killed during Rio police operation, including drug kingpin
-
Iran suffers new blow as Israel kills intel chief
-
Slovakia curbs diesel sales, ups prices for foreigners
-
Oscar-winner Sean Penn meets troops in frontline Ukraine
-
Thousands rally in Istanbul to mark year since mayor's arrest
-
WNBA, players union agree 'transformative' labor deal: official
-
US Fed holds rates unchanged over 'uncertain' Iran war implications
-
Senegal govt calls for investigation into Cup of Nations decision
-
From Faraja to Sepah: Iran's multiple security forces
-
Billionaire Dyson buys 50 percent stake in Bath rugby
-
Senegal demands 'corruption' probe over AFCON decision as Morocco defend appeal
-
The platypus is even weirder than thought, scientists discover
-
PSG's Barcola ruled out for several weeks with ankle injury
-
Colombia detains suspect in 2023 killing of Ecuador politician
-
Iran condemned as UN maritime body holds emergency talks on Mideast shipping
-
Iraqi Kurdish shepherds stoic in face of yet another war
-
Iran women's football team return after asylum tussle
-
US launches new era of drug war with Latin American allies
-
How many cargo ships are passing Hormuz strait?
-
'Free France': Macron reveals name of Europe's largest warship
-
Oil surges as Iran gas facilities hit, stocks slide
-
Foreign press group slams Israeli police for breaking journalist's wrist
-
McIlroy happy with back injury recovery as Masters looms
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Tuesday, February 3, 2026, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 567381.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53322, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until February 17, 2026, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53322.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
P.Silva--AMWN